300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
Indonesia
Middle East
United Kingdom
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
U.S. Venture Partners, VC Fund

U.S. Venture Partners

VC Fund

Menlo Park, United States

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the pastthirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

Total investments:
427
Last investment:
Lead investor:
33%
Last fund:

Last updated:

Industries U.S. Venture Partners invests in

SoftwareHealth CareInformation TechnologyMedicalManufacturing

Stages U.S. Venture Partners invests in

Series BSeries CSeries AFunding RoundSeries D

Countries U.S. Venture Partners invests in

United StatesIsraelCanadaFranceChina

Round sizes

Series A $5M–$42MSeries B $7M–$51MSeries C $7.8M–$68M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$5M–$42M
Series B
$7M–$51M
Series C
$7.8M–$68M

Investment Focus

Industry

  • Software 61 (14%)
  • Health Care 51 (12%)
  • Information Technology 32 (7%)
  • Medical 28 (7%)
  • Manufacturing 27 (6%)
See all 213 industries →

Stage

  • Series B 100 (23%)
  • Series C 80 (19%)
  • Series A 71 (17%)
  • Funding Round 52 (12%)
  • Series D 35 (8%)
See all 12 stages →

Country

  • United States 197 (46%)
  • Israel 13 (3%)
  • Canada 3 (1%)
  • France 2 (0%)
  • China 1 (0%)
See all 6 countries →

Team

NameTitleInvestmentsLinksEmail
Phil Young
Phil Young Senior Advisor
Senior Advisor Total investments: 9
Find email
Casey Tansey
Casey Tansey General Partner
General Partner Total investments: 24 Find email
Dafina Toncheva
Dafina Toncheva General Partner
General Partner Total investments: 36
Find email
Dale Holladay
Dale Holladay CPA/CFO
CPA/CFO Total investments: 0
Find email
Jacques Benkoski
Jacques Benkoski General Partner
General Partner Total investments: 20
Find email
See all 9 team members →

Investments

CompanyDescriptionRoundLinks
Maneva Maneva
Maneva develops video-to-action artificial intelligence systems for manufacturing environments, using computer vision and deep learning to analyze production processes and support operational decision-making in real time. Its platform helps manufacturers address quality assurance, downtime reduction, productivity monitoring, and workplace safety byconverting visual data from factory-floor cameras into actionable insights and automated responses. The company offers solutions such as VITA for defect detection, product verification, and equipment monitoring, as well as ALIS, an AI-powered line supervision system that tracks production efficiency and safety compliance. Maneva's technology is designed to work with existing camera infrastructure and can be applied across industries, including food and beverage, pharmaceuticals, electronics, automotive, steel, and distribution operations. The company focuses on helping manufacturers improve production consistency, identify operational issues, and monitor factory processes through AI-driven visual analysis. $27M / Series A / Jun 10, 2026
Cagent Vascular Cagent Vascular
Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. $41M / Series D / May 19, 2026
Nervonik Nervonik
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. $52.5M / Series B / Apr 27, 2026
Route 92 Medical Route 92 Medical
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. $50M / Private Equity / Apr 07, 2026
Slang Slang
Slang.ai is a digital phone concierge that answers questions, takes reservations, and satisfies callers. $28M / Series B / Feb 24, 2026
Adaptive6 Adaptive6
Adaptive6 is a Cloud Cost Governance platform that addresses both cloud and code, providing a comprehensive approach to managing costs effectively. The platform empowers engineers to take immediate action on cloud costs and prevents waste at the code level, enhancing efficiency in cloud management. $28M / Series A / Jan 28, 2026
Okami Medical Okami Medical
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. $45M / Series F / Nov 19, 2025
Apono Apono
Apono helps companies become secure and compliant while maintaining their productivity and agility. The company aims to simplify how teams manage access to critical systems by automating the provisioning and deprovisioning of permissions based on real-time needs, ensuring only the right people have access at the right time. $34M / Series B / Nov 18, 2025
Weave Weave
Weave provides an artificial intelligence collaboration platform for biomedicine. The company is headquartered in the United States. $20M / Series A / Oct 16, 2025
Sparrow Pharmaceuticals Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company addressing metabolic dysfunction from excess cortisol. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to deliver improved outcomes for patients who struggle to control diabetes and related metabolic conditions with currentoptions. Its lead product, clofutriben, is an oral, small molecule, designed to target the source of active intracellular cortisol in key tissues.The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States. $95M / Series B / Sep 24, 2025
See all 427 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
Indonesia
Middle East
United Kingdom
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does U.S. Venture Partners invest in?

U.S. Venture Partners invests primarily in Software, Health Care and Information Technology startups, most often at Series B and Series C stage. Most of the 427 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is U.S. Venture Partners's check size?

U.S. Venture Partners typically joins rounds of $5M–$42M at Series A, $7M–$51M at Series B and $7.8M–$68M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds U.S. Venture Partners participates in.

How do I contact U.S. Venture Partners?

Public channels for U.S. Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at U.S. Venture Partners?

The team at U.S. Venture Partners includes Phil Young (Senior Advisor), Casey Tansey (General Partner) and Dafina Toncheva (General Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
U.S. Venture Partners U.S. Venture Partners Find emails